Conjugation of functionalized gadolinium metallofullerenes with IL-13 peptides for targeting and imaging glial tumors

Helen Fillmore; Michael D. Shultz; Scott C. Henderson; Patricia Cooper; William C. Broaddus; Zhi Jian Chen; Chun-Ying Shu; Jianfei Zang; Jiechao Ge; Harry C. Dorn; Frank Corwin; John Wilson; Panos P. Fatouros

doi:10.2217/nnm.10.134

Conjugation of functionalized gadolinium metallofullerenes with IL-13 peptides for targeting and imaging glial tumors

Helen Fillmore, Michael D. Shultz, Scott C. Henderson, Patricia Cooper, William C. Broaddus, Zhi Jian Chen, Chun-Ying Shu, Jianfei Zang, Jiechao Ge, Harry C. Dorn, Frank Corwin, John Wilson, Panos P. Fatouros

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Glioblastoma multiforme is the most common and most lethal primary brain tumor in humans, with median survival of approximately 1 year. Owing to the ability of glioma cells to aggressively infiltrate normal brain tissue and survive exposure to current adjuvant therapies, there is a great need for specific targeted nanoplatforms capable of delivering both therapeutic and imaging agents directly to invasive tumor cells.
Method: Gadolinium-containing endohedral fullerenes, highly efficient contrast agents for MRI, were functionalized and conjugated with a tumor-specific peptide and assessed for their ability to bind to glioma cells in vitro.
Results: We report the successful conjugation of the carboxyl functionalized metallofullerene Gd_{3N@C₈₀(OH)_-26(CH₂CH₂COOH)_-16 to IL-13 peptides and the successful targeting ability towards brain tumor cells that overexpress the IL-13 receptor (IL-13Rα2).}
Conclusion: These studies demonstrate that IL-13 peptide-conjugated gadolinium metallofullerenes could serve as a platform to deliver imaging and therapeutic agents to tumor cells.

Original language	English
Pages (from-to)	449-458
Journal	Nanomedicine
Volume	6
Issue number	3
DOIs	https://doi.org/10.2217/nnm.10.134
Publication status	Published - Apr 2011

Access to Document

10.2217/nnm.10.134

Cite this

@article{1879d8c9a79e429cabb975146e904866,

title = "Conjugation of functionalized gadolinium metallofullerenes with IL-13 peptides for targeting and imaging glial tumors",

abstract = "Background: Glioblastoma multiforme is the most common and most lethal primary brain tumor in humans, with median survival of approximately 1 year. Owing to the ability of glioma cells to aggressively infiltrate normal brain tissue and survive exposure to current adjuvant therapies, there is a great need for specific targeted nanoplatforms capable of delivering both therapeutic and imaging agents directly to invasive tumor cells. Method: Gadolinium-containing endohedral fullerenes, highly efficient contrast agents for MRI, were functionalized and conjugated with a tumor-specific peptide and assessed for their ability to bind to glioma cells in vitro. Results: We report the successful conjugation of the carboxyl functionalized metallofullerene Gd3N@C80(OH)-26(CH2CH2COOH)-16 to IL-13 peptides and the successful targeting ability towards brain tumor cells that overexpress the IL-13 receptor (IL-13Rα2). Conclusion: These studies demonstrate that IL-13 peptide-conjugated gadolinium metallofullerenes could serve as a platform to deliver imaging and therapeutic agents to tumor cells.",

author = "Helen Fillmore and Shultz, {Michael D.} and Henderson, {Scott C.} and Patricia Cooper and Broaddus, {William C.} and Chen, {Zhi Jian} and Chun-Ying Shu and Jianfei Zang and Jiechao Ge and Dorn, {Harry C.} and Frank Corwin and John Wilson and Fatouros, {Panos P.}",

year = "2011",

month = apr,

doi = "10.2217/nnm.10.134",

language = "English",

volume = "6",

pages = "449--458",

journal = "Nanomedicine",

issn = "1743-5889",

publisher = "Future Medicine Ltd.",

number = "3",

}

TY - JOUR

T1 - Conjugation of functionalized gadolinium metallofullerenes with IL-13 peptides for targeting and imaging glial tumors

AU - Fillmore, Helen

AU - Shultz, Michael D.

AU - Henderson, Scott C.

AU - Cooper, Patricia

AU - Broaddus, William C.

AU - Chen, Zhi Jian

AU - Shu, Chun-Ying

AU - Zang, Jianfei

AU - Ge, Jiechao

AU - Dorn, Harry C.

AU - Corwin, Frank

AU - Wilson, John

AU - Fatouros, Panos P.

PY - 2011/4

Y1 - 2011/4

N2 - Background: Glioblastoma multiforme is the most common and most lethal primary brain tumor in humans, with median survival of approximately 1 year. Owing to the ability of glioma cells to aggressively infiltrate normal brain tissue and survive exposure to current adjuvant therapies, there is a great need for specific targeted nanoplatforms capable of delivering both therapeutic and imaging agents directly to invasive tumor cells. Method: Gadolinium-containing endohedral fullerenes, highly efficient contrast agents for MRI, were functionalized and conjugated with a tumor-specific peptide and assessed for their ability to bind to glioma cells in vitro. Results: We report the successful conjugation of the carboxyl functionalized metallofullerene Gd3N@C80(OH)-26(CH2CH2COOH)-16 to IL-13 peptides and the successful targeting ability towards brain tumor cells that overexpress the IL-13 receptor (IL-13Rα2). Conclusion: These studies demonstrate that IL-13 peptide-conjugated gadolinium metallofullerenes could serve as a platform to deliver imaging and therapeutic agents to tumor cells.

AB - Background: Glioblastoma multiforme is the most common and most lethal primary brain tumor in humans, with median survival of approximately 1 year. Owing to the ability of glioma cells to aggressively infiltrate normal brain tissue and survive exposure to current adjuvant therapies, there is a great need for specific targeted nanoplatforms capable of delivering both therapeutic and imaging agents directly to invasive tumor cells. Method: Gadolinium-containing endohedral fullerenes, highly efficient contrast agents for MRI, were functionalized and conjugated with a tumor-specific peptide and assessed for their ability to bind to glioma cells in vitro. Results: We report the successful conjugation of the carboxyl functionalized metallofullerene Gd3N@C80(OH)-26(CH2CH2COOH)-16 to IL-13 peptides and the successful targeting ability towards brain tumor cells that overexpress the IL-13 receptor (IL-13Rα2). Conclusion: These studies demonstrate that IL-13 peptide-conjugated gadolinium metallofullerenes could serve as a platform to deliver imaging and therapeutic agents to tumor cells.

U2 - 10.2217/nnm.10.134

DO - 10.2217/nnm.10.134

M3 - Article

SN - 1743-5889

VL - 6

SP - 449

EP - 458

JO - Nanomedicine

JF - Nanomedicine

IS - 3

ER -

Conjugation of functionalized gadolinium metallofullerenes with IL-13 peptides for targeting and imaging glial tumors

Abstract

Access to Document

Fingerprint

Cite this